Trials / Completed
CompletedNCT00419250
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
A Phase 1, Multi-center, Open-label Study of the Safety and Efficacy of a Stepwise Dose-escalation Schedule of Lenalidomide Monotherapy in Subjects With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of lenalidomide and to define the maximum tolerated escalation dose level (MTEDL) when administered by a stepwise dose-escalation schedule in subjects with relapsed or refractory B-cell CLL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lenalidomide | |
| DRUG | lenalidomide | |
| DRUG | lenalidomide | |
| DRUG | lenalidomide | |
| DRUG | lenalidomide |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2010-02-01
- Completion
- 2010-06-01
- First posted
- 2007-01-08
- Last updated
- 2019-11-08
Locations
35 sites across 7 countries: United States, Canada, Germany, Italy, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00419250. Inclusion in this directory is not an endorsement.